UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER ~~PURSUANT~~ ~~TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934~~

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission file number: 001-40231

Universe Pharmaceuticals INC

265 Jingjiu Avenue ~~Jinggangshan Economic and Technological Development Zone Ji’an, Jiangxi, China 343100 +86-0796-8403309 (Address of principal executive offices)~~

Jinggangshan Economic and Technological Development Zone

Ji’an, Jiangxi, China 343100

+86-0796-8403309

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

~~Explanatory~~Closing ~~Note~~of Acquisition of Best Praise International Limited

As previously disclosed in the Report on Form 6-K filed by Universe Pharmaceuticals INC (the “Company”) is ~~filing~~with ~~this~~the ~~current~~U.S. ~~report~~Securities and Exchange Commission on ~~Form~~June 26, 2026 (the “Prior 6-K”), the Company entered into a Share Purchase Agreement dated June 17, 2026 (the “SPA”) with Ms. Lu Shanshan (“Ms. Lu”), pursuant to ~~report~~which ~~its~~the ~~financial~~Company ~~results~~agreed asto acquire 100% of the issued shares (the “Target Shares”) of Best Praise International Limited (the “Target”). The Target holds five patents in the People’s Republic of China relating to pharmaceutical compounds and ~~for~~drug delivery technologies in the ~~six~~areas ~~months~~of ~~ended~~age-related ~~March~~diseases, 31neurodegenerative conditions, cognitive ~~2026~~disorders, and tocardiovascular-related ~~discuss~~pharmaceutical applications. The description of the SPA and the transactions contemplated ~~its~~thereby, ~~recent~~as ~~corporate~~set ~~developments~~forth in the Prior 6-K, is incorporated herein by reference.

~~Attached~~On asJune ~~exhibits~~30, 2026, the Company completed the acquisition of the Target Shares pursuant to ~~this~~the ~~current~~SPA (the “Closing”). In connection with the Closing, as of the date of this report, onthe ~~Form~~Company ~~6-K~~has ~~are:~~issued all 4,376,552 Class A ordinary shares (the “Consideration Shares”) to the recipients in full satisfaction of the consideration under the SPA. The Consideration Shares were issued as restricted securities under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon an exemption from the registration requirements thereof.

	(1)	the unaudited condensed interim consolidated financial statements and related notes as Exhibit 99.1;
	(2)	Management’s Discussion and Analysis of Financial Condition and Results of Operations as Exhibit 99.2;
	(3)	Interactive Data Files as Exhibit 101, in accordance with Rule 405 of Regulation S-T.

Pursuant to the SPA, the Company has agreed to certain resale registration provisions with respect to the Consideration Shares, subject to applicable securities laws, SEC rules, Nasdaq rules, and the terms set forth in the SPA.

A copy of the SPA was previously filed as Exhibit 10.1 to the Prior 6-K and is incorporated herein by reference. The foregoing description of the SPA does not purport to be complete and is qualified in its entirety by reference to the full text of the SPA.

As of the date of this report, following the issuance of the Consideration Shares, the Company has 5,008,313 Class A ordinary shares and 16,077 Class B ordinary shares issued and outstanding.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements in this current report with respect to the Company’s current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of the Company. Forward-looking statements include, but are not limited to, those statements using words such as “believe,” “expect,” “plans,” “strategy,” “prospects,” “forecast,” “estimate,” “project,” “anticipate,” “aim,” “intend,” “seek,” “may,” “might,” “could” or “should,” and words of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management’s assumptions, judgments and beliefs in light of the information currently available to it. The Company cautions investors that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission. Therefore, investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from those set forth in the forward-looking statements.

All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Unaudited Consolidated Financial Statements and Related Notes as of March 31, 2026 and for the Six Months Ended March 31, 2026 and 2025
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations
101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities ~~and~~ Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Universe Pharmaceuticals INC.
	Universe Pharmaceuticals INC
Date: July 29, 2026	By:	/s/ Gang Lai
Date: July 31, 2026	By:	/s/ Gang Lai
		Gang Lai
		Chief Executive Officer

Filing Compare · Universe Pharmaceuticals INC